Guest guest Posted March 30, 2011 Report Share Posted March 30, 2011 Vertex Notches Another Victory Minyanville.com What Vertex has going for it is a promising one-two punch of late-stage developmental drugs to treat hepatitis C and cystic fibrosis, two troublesome diseases that present large market opportunities. Last month, Vertex said its cystic fibrosis VX-770 ... Cyplasin Biomedical Ltd Announces Name Change And Creation of a Subsidiary C ... CNW Group (press release) The Company is pleased to announce that in order to better reflect multiple new product development opportunities and to continue its current product development programs for Hepatitis C; will effective immediately, change its name to Compass ... See all stories on this topic » Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will ... PharmaLive.com (press release) CORK, Ireland, March 29, 2011 /PRNewswire/ -- Tibotec Pharmaceuticals announced today that four abstracts reporting research findings with TMC435, the company's investigational hepatitis C protease inhibitor, have been accepted for presentation at the ... See all stories on this topic » Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.